伏立康唑基因多态性与血药浓度的研究进展

摘要/Abstract

摘要： 伏立康唑（Voriconazole， VRZ）是一种广谱抗真菌药物，广泛用于治疗侵袭性真菌感染。然而，VRZ的药代动力学特性存在显著个体差异，包括非线性药代动力学和不良反应。基因多态性，特别是与CYP酶相关的基因多态性，对VRZ的代谢速率和血药浓度有显著影响。在VRZ治疗过程中，根据个体基因型和血药浓度调整药物剂量至关重要。本研究综述了VRZ治疗窗和不良反应等问题，强调基因多态性在VRZ药代动力学和药效学中的关键作用。特别分析了CYP家族基因（如CYP2C19、CYP2C9、CYP3A）、POR基因、FMO3基因以及转运蛋白基因（如SLCO2B1、ABCB1）多态性对VRZ血药浓度及个体化治疗策略的影响，为VRZ的个体化治疗提供科学依据，减少不良反应，提升治疗效果，并为未来研究指明方向。

关键词: font-size:medium, ">伏立康唑；基因多态性；血药浓度；个体化治疗；疗效；不良反应

Abstract: Voriconazole (VRZ) is a broad-spectrum antifungal drug widely used to treat aggressive fungal infections. However， there are significant individual differences in the pharmacokinetic characteristics of VRZ， including nonlinear pharmacokinetics and high adverse reaction rates. Gene polymorphisms， especially those related to CYP enzyme， have significant effects on the metabolic rate and blood concentration of VRZ. During VRZ treatment， it is important to adjust the drug dose according to the individual genotype and blood concentration. In this study， the narrow therapeutic window and high incidence of adverse reactions of VRZ were discussed， emphasizing the key role of gene polymorphism in the pharmacokinetics and pharmacodynamics of VRZ. In particular， the effects of polymorphisms of CYP family genes (such as CYP2C19， CYP2C9， CYP3A)， POR genes， FMO3 genes， and transporter genes (such as SLCO2B1， ABCB1) on VRZ blood concentration and individual therapy strategies were analyzed. The aim is to provide scientific basis for the individualized treatment of VRZ by summarizing the current research results， reduce the adverse reactions， improve the therapeutic effect， and point out the direction for future research.

Key words: font-size:medium, ">Voriconazole； Genetic polymorphisms； Blood drug concentrations；Individualized therapy； Curative effect； Adverse reaction

中图分类号:

李雅暄1, 宋沧桑1, 2, 李兴德1, 2, 王国徽2, 毛盼盼2, 马雪娇2. 伏立康唑基因多态性与血药浓度的研究进展[J]. 中国药物评价, 2024, 41(4): 307-313.

LI Ya-xuan1, SONG Cang-sang1, 2, LI Xing-de1, 2, WANG Guo-hui2, MAO Pan-pan2, MA Xue-jiao2. Research Progress on the Relationship between Voriconazole Genetic Polymorphisms and Blood Drug Concentrations[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2024, 41(4): 307-313.

参考文献

[1] Rosanova MT， Bes D， Serrano Aguilar P， et al. Efficacy and safety of voriconazole in immunocompromised patients： systematic review and meta-analysis [J]. Infectious diseases (London， England)， 2018， 50(7)： 489-494.
     [2] Chiou CC， Groll AH， Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer [J]. The oncologist， 2000， 5(2)： 120-135.
     [3] Herbrecht R， Denning DW， Patterson TF， et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J]. The New England journal of medicine， 2002， 347(6)： 408-415.
     [4] Pappas PG， Kauffman CA， Andes DR， et al. Clinical Practice Guideline for the Management of Candidiasis： 2016 Update by the Infectious Diseases Society of America [J]. Clinical infectious diseases： an official publication of the Infectious Diseases Society of America， 2016， 62(4)： e1-50.
     [5] Mikus G， Scholz IM， Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole [J]. Pharmacogenomics， 2011， 12(6)： 861-872.
     [6] Blanco-Dorado S， Maroas O， Latorre-Pellicer A， et al. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations： A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study [J]. Pharmacotherapy， 2020， 40(1)： 17-25.
     [7] van den Born DA， Mrtson AG， Veringa A， et al. Voriconazole exposure is influenced by inflammation： A population pharmacokinetic model [J]. International journal of antimicrobial agents， 2023， 61(4)： 106750.
     [8] Wei JF. The Effects of Genetic Polymorphisms in Pharmacokinetics and Pharmacodynamics Parameters [J]. Current drug metabolism， 2018， 19(14)： 1140.
     [9] Zhou SF， Liu JP， Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact [J]. Drug metabolism reviews， 2009， 41(2)： 289-295.
     [10] Barbarino JM， Owusu Obeng A， Klein TE， et al. PharmGKB summary： voriconazole pathway， pharmacokinetics [J]. Pharmacogenetics and genomics， 2017， 27(5)： 201-209.
     [11] Zanger UM， Schwab M. Cytochrome P450 enzymes in drug metabolism： regulation of gene expression， enzyme activities， and impact of genetic variation [J]. Pharmacology & therapeutics， 2013， 138(1)： 103-141.
     [12] 杨秀乔. 15个SNPs位点多态性与云南汉族男性雄激素性脱发的相关分析 [D]. 昆明医科大学， 2017.
     [13] Tsamandouras N， Guo Y， Wendling T， et al. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population [J]. Pharmacogenetics and genomics， 2017， 27(1)： 27-38.
     [14] Endo-Tsukude C， Sasaki JI， Saeki S， et al. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer： Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters [J]. Biological & pharmaceutical bulletin， 2018， 41(1)： 47-56.
     [15] Kubo K， Ohara M， Tachikawa M， et al. Population differences in S-warfarin pharmacokinetics among African Americans， Asians and whites： their influence on pharmacogenetic dosing algorithms [J]. The pharmacogenomics journal， 2017， 17(6)： 494-500.
     [16] Theuretzbacher U， Ihle F， Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole [J]. Clinical pharmacokinetics， 2006， 45(7)： 649-663.
     [17] Hyland R， Jones BC， Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J]. Drug metabolism and disposition： the biological fate of chemicals， 2003， 31(5)： 540-547.
     [18] Yanni SB， Annaert PP， Augustijns P， et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes [J]. Drug metabolism and disposition： the biological fate of chemicals， 2008， 36(6)： 1119-1125.
     [19] Murayama N， Imai N， Nakane T， et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole， a new anti-fungal agent， in human liver microsomes [J]. Biochemical pharmacology， 2007， 73(12)： 2020-2026.
     [20] Roffey SJ， Cole S， Comby P， et al. The disposition of voriconazole in mouse， rat， rabbit， guinea pig， dog， and human [J]. Drug metabolism and disposition： the biological fate of chemicals， 2003， 31(6)： 731-741.
     [21] Scholz I， Oberwittler H， Riedel KD， et al. Pharmacokinetics， metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype [J]. British journal of clinical pharmacology， 2009， 68(6)： 906-915.
     [22] Scott SA， Sangkuhl K， Shuldiner AR， et al. PharmGKB summary： very important pharmacogene information for cytochrome P450， family 2， subfamily C， polypeptide 19 [J]. Pharmacogenetics and genomics， 2012， 22(2)： 159-165.
     [23] Hicks JK， Bishop JR， Sangkuhl K， et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [J]. Clinical pharmacology and therapeutics， 2015， 98(2)： 127-134.
     [24] Shang S， Cheng L， Li X， et al. Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients [J]. Mycoses， 2020， 63(11)： 1181-1190.
     [25] Moriyama B， Falade-Nwulia O， Leung J， et al. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy： avoiding a serious adverse drug interaction [J]. Mycoses， 2011， 54(6)： e877-879.
     [26] Moriyama B， Jarosinski PF， Figg WD， et al. Pharmacokinetics of intravenous voriconazole in obese patients： implications of CYP2C19 homozygous poor metabolizer genotype [J]. Pharmacotherapy， 2013， 33(3)： e19-22.
     [27] 王百乔，赵震宇，韩敏，等. 伏立康唑治疗侵袭性真菌感染致肝损伤影响因素及CYP2C19基因多态性[J]. 中华医院感染学杂志， 2021， 31(13)： 1957-1962.
     [28] Moriyama B， Obeng AO， Barbarino J， et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [J]. Clinical pharmacology and therapeutics， 2017， 102(1)： 45-51.
     [29] Dolton MJ， Mikus G， Weiss J， et al. Understanding variability with voriconazole using a population pharmacokinetic approach： implications for optimal dosing [J]. The Journal of antimicrobial chemotherapy， 2014， 69(6)： 1633-41.
     [30] 桂明珠. 伏立康唑治疗儿童侵袭性真菌感染的血药浓度意义与潜在影响因素研究 [D]. 上海交通大学，2020.
     [31] Fan X， Zhang H， Wen Z， et al. Effects of CYP2C19， CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients [J]. Pharmacogenetics and genomics， 2022， 32(4)： 152-8.
     [32] Wojnowski L. Genetics of the variable expression of CYP3A in humans [J]. Therapeutic drug monitoring， 2004， 26(2)： 192-9.
     [33] Klyushova LS， Perepechaeva ML， Grishanova AY. The Role of CYP3A in Health and Disease [J]. Biomedicines， 2022， 10(11).
     [34] McMillan DM， El-Sherbeni AA， Richards J， et al. Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats [J]. Brain research bulletin， 2020， 164： 400-6.
     [35] 付婷婷. 细胞色素P450 3A4介导的咪达唑仑代谢区域选择性分子机制的理论研究 [D]， 2023.
     [36] He HR， Sun JY， Ren XD， et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole [J]. European journal of clinical microbiology & infectious diseases： official publication of the European Society of Clinical Microbiology， 2015， 34(4)： 811-9.
     [37] 邵贝贝. 基于CYP2C19、CYP2C9、CYP3A4、ABCB1基因多态性的伏立康唑个体化用药研究 [D]. 2017.
     [38] Gautier-Veyret E， Fonrose X， Tonini J， et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation： impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels [J]. Antimicrobial agents and chemotherapy， 2015， 59(4)： 2305-2314.
     [39] Yamazaki H， Nakamoto M， Shimizu M， et al. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles [J]. British journal of clinical pharmacology， 2010， 69(6)： 593-597.
     [40] Lee S， Kim BH， Nam WS， et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers [J]. Journal of clinical pharmacology， 2012， 52(2)： 195-203.
     [41] Booyse RP， Twesigomwe D， Hazelhurst S. Characterization of POR haplotype distribution in African populations and comparison with other global populations [J]. Pharmacogenomics， 2022， 23(14)： 771-82.
     [42] Miller WL， Agrawal V， Sandee D， et al. Consequences of POR mutations and polymorphisms [J]. Molecular and cellular endocrinology， 2011， 336(1-2)： 174-9.
     [43] Zeng G， Wang L， Shi L， et al. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies： influence of loading dose， procalcitonin， and pregnane X receptor polymorphisms [J]. European journal of clinical pharmacology， 2020， 76(4)： 515-23.
     [44] Aiuchi N， Nakagawa J， Sakuraba H， et al. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole [J]. Pharmacology research & perspectives， 2022， 10(2)： e00935.
     [45] Cashman JR. Human flavin-containing monooxygenase： substrate specificity and role in drug metabolism [J]. Current drug metabolism， 2000， 1(2)： 181-91.
     [46] Dapía I， García I， Martinez JC， et al. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics： AN exploratory study in a Spanish population [J]. International journal of antimicrobial agents， 2019， 54(4)： 463-70.
     [47] Chuwongwattana S， Jantararoungtong T， Prommas S， et al. Impact of CYP2C19， CYP3A4， ABCB1， and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections [J]. Pharmacol Res Perspect， 2020， 8(6)： e00665.
     [48] Wang X， Zhao J， Wen T， et al. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia [J]. Pharmacology， 2021， 106(3-4)： 202-10.
     [49] Li Y， Zhang Y， Zhao J， et al. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration： data from a real-life clinical setting in the Chinese population [J]. Journal of chemotherapy (Florence， Italy)， 2023： 1-11.
     [50] Yamada T， Mino Y， Naito T， et al. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients [J]. Journal of infection and chemotherapy： official journal of the Japan Society of Chemotherapy， 2019， 25(12)： 1019-25.
     [51] Johnson M， Patel D， Matheny C， et al. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin [J]. Drug metabolism and disposition： the biological fate of chemicals， 2017， 45(1)： 27-34.
     [52] Lee SW， Oh J， Kim AH， et al. Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers [J]. The pharmacogenomics journal， 2020， 20(6)： 792-800.
     [53] Allegra S， Fatiguso G， Francia S， et al. Pharmacogenetic of voriconazole antifungal agent in pediatric patients [J]. Pharmacogenomics， 2018， 19(11)： 913-25.
     [54] Weiss J， Ten Hoevel MM， Burhenne J， et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole [J]. Journal of clinical pharmacology， 2009， 49(2)： 196-204.
     [55] 袁雅君，吕晓赞，周武源，等. 区域创新中前沿科学发展策略实证分析——以浙江省基因治疗为例 [J]. 科技通报，2022， 38(10)： 113-124.
     [56] 王利霞，甘泉，甘才斌，等. 基于生物信息学分析乌司奴单抗治疗寻常型银屑病不应答的关键基因和信号通路[J]. 实用药物与临床， 2023， 26(6)： 494-499.